Trial reportCancer medicine2026
Structured Exercise During Chemotherapy for Locally Advanced or Metastatic Pancreatic Cancer: A Single-Arm, Feasibility Trial.
Trial report in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEvidence on structured exercise during systemic treatment for patients with locally advanced or metastatic pancreatic cancer is still limited, and detailed feasibility data in real-world clinical settings remain scarce. This study aimed to assess the feasibility, safety, and preliminary efficacy of a 12-week exercise intervention in this population.
methodsIn this prospective single-arm trial, 20 patients undergoing chemotherapy participated in a supervised exercise program comprising aerobic and resistance training, delivered twice weekly for 12 weeks. Participants could choose between supervised gym-based or home-based sessions. Primary outcomes included recruitment, retention, attendance, adherence, tolerance, and safety. Secondary outcomes were changes in physical fitness and patient-reported outcomes. Descriptive statistics and paired t-tests or Wilcoxon signed-rank tests were used for analyses. Exploratory subgroup analyses were conducted by tumor stage and exercise delivery mode.
resultsThe recruitment rate was 80%, with a 43% dropout rate primarily due to disease progression or treatment-related toxicities. Median session attendance was 79%, and adherence to prescribed exercise volume reached 77%. Only three non-serious adverse events were reported. Significant improvements were observed in grip strength (p = 0.049), total weekly physical activity (p = 0.024), and time spent in moderate-intensity activity (p < 0.001). Emotional (p = 0.022) and social functioning (p = 0.048) significantly improved, while appetite loss decreased (p = 0.010). Subgroup analyses suggested greater benefits in patients with stage IV disease and those in the home-based group.
conclusionsExercise during chemotherapy appears feasible and safe for patients with advanced/metastatic pancreatic cancer, and it may help maintain physical fitness, enhance emotional and social well-being, and alleviate appetite loss. However, different strategies are required to reduce the dropout rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.